New therapeutics for myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1470-1474

  List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Hedgehog inhibitors; P38 MAPK; Rigosertib; TGF

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARRY 614; AZACITIDINE; AZANUCLEOSIDE DERIVATIVE; BETA CATENIN; C 21359; CC 486; CENERSEN; CHR 79888; CYTARABINE; GROWTH FACTOR; HYDROXYUREA; INCB 24360; LENALIDOMIDE; LY 2157299; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEOSIDE DERIVATIVE; PF 04449913; RIGOSERTIB; SARIDEGIB; SGI 110; SILTUXIMAB; SOTATERCEPT; THYMOCYTE ANTIBODY; TOSEDOSTAT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME DELETION 5; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG TARGETING; DYSGEUSIA; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MUSCLE SPASM; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 5; GLYCINE; HUMANS; HYDROXAMIC ACIDS; MYELODYSPLASTIC SYNDROMES; NEOPLASTIC STEM CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SEQUENCE DELETION; SULFONES; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84868213006     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.010     Document Type: Review

References (45)

1. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464(7290):852-857.
2. Wei S., Xianghong C., Rocha K., Qi D., Tao J., Gjertsen N., et al. Myeloid-derived suppressor cells (MDSC) are effectors of bone marrow suppression in lower risk myelodysplastic syndromes (MDS). Blood 2009, 114. Abstract 597 [ASH Annual Meeting Abstracts].
3. Kristinsson S.Y., Björkholm M., Hultcrantz M., Derolf Å.R., Landgren O., Goldin L.R. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011, 29(21):2897-2903.
4. Maratheftis C.I., Andreakos E., Moutsopoulos H.M., Voulgarelis M. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 2007, 13:1154-1160.
5. Hofmann W.K., de Vos S., Komor M., Hoelzer D., Wachsman W., Koeffler H.P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002, 100:3553.
6. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 112:1534.
7. Starczynowski D.T., Vercauteren S., Telenius A., Sung S., Tohyama K., Brooks-Wilson A., et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008, 111:1534.
8. Epling-Burnette P.K., Painter J.S., Rollison D.E., Ku E., Vendron D., Widen R., et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 2007, (4):659-667.
9. Walter M.J., Shen D., Ding L., Shao J., Koboldt D.C., Chen K., et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012, 366(12):1090-1098.
10. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451(7176):335-339.
11. Barlow J.L., Drynan L.F., Hewett D.R., Holmes L.R., Lorenzo-Abalde S., Lane A.L., et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med 2010, 16(1):59-66.
12. Wei S., Chen X., Rocha K., Epling-Burnette P.K., Djeu J.Y., Liu Q., et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009, 106:12974-12979.
13. Wei S., Chen X., McGraw K., Zhang L., Komrokji R., Clark J., et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2012, (April). 10.1038/onc.2012.139.
14. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102(8):3025-3027.
15. Sloand E.M., Wu C.O., Greenberg P., Young N., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26(15):2505-2511.
16. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110(3):847-850.
17. Mailloux A.W., Sugimori C., Komrokji R.S., Maciejewski J.P., Sekeres M.A., Paquette R., et al. Expansion of effector regulatory T-cells represents a novel prognostic factor marking escape from immune surveillance in developing myelodysplastic syndrome. J Immunol 2012, [Epub ahead of print].
18. Bandow K., Maeda A., Kakimoto K., Kusuyama J., Shamoto M., Ohnishi T., et al. Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation. Biochem Biophys Res Commun 2010, 402(4):755-761.
19. De Luca K., Frances-Duvert V., Asensio M.J., Ihsani R., Debien E., Taillardet M., et al. The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia 2009, 23(11):2063-2074.
20. Ustun C., Miller J.S., Munn D.H., Weisdorf D.J., Blazar B.R. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. Blood 2011, 118(19):5084-5095.
21. Zhou L., Nguyen A.N., Sohal D., Ying Ma J., Pahanish P., Gundabolu K., et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008, 112(8):3434-3443.
22. Schmierer B., Hill C.S. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007, 8(12):970-982.
23. Bhagat T.D., Zhou L., Sokol L., Mantzaris I., Gundabolu K., Gordon S.A.K., et al. Mir-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling. Blood 2011, 118. Abstract 3813 [ASH Annual Meeting Abstracts].
24. Zhou L., McMahon C., Bhagat T., Alencar C., Yu Y., Fazzari M., et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 2011, 71(3):955-963.
25. Raje N., Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010, 12(5):586-597.
26. van Rhee F., Fayad L., Voorhees P., Furman R., Lonial S., Borghaei H., et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010, 28(August (23)):3701-3708.
27. Dutt S., Narla A., Lin K., Mullally A., Abayasekara N., Megerdichian C., et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011, 117:2567-2576.
28. http://www.concertpharma.com/research/index.html.
29. Cortes J., Kantarjian H., Ball E.D., Dipersio J., Kolitz J.E., Fernandez H.F., et al. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 2012, 118(2):418-427.
30. Prébet T., Gore S.D., Esterni B., Gardin C., Itzykson R., Thepot S., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29(24):3322-3327.
31. Chapman C.M., Sun X., Roschewski M., Aue G., Farooqui M., Stennett L., et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012, 18(7):1979-1991.
32. Löwenberg B., Morgan G., Ossenkoppele G.J., Burnett A.K., Zachée P., Dührsen U., et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 2010, 28(28):4333-4338.
33. Porras A., Zuluaga S., Black E., Valladares A., Alvarez A.M., Ambrosino C., et al. P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 2004, 15(2):922-933.
34. Navas T.A., Mohindru M., Estes M., Ma J.Y., Sokol L., Pahanish P., et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006, 108(December (13)):4170-4177.
35. Komrokji R.S., List A.F., Khoury H.J., Lancet J.E., Jabbour E., Foudray M.C., et al. Phase 1 Dose-escalation/expansion study of the p38/Tie2 inhibitor ARRY-614 in patients with IPSS low/int-1 risk myelodysplastic syndromes. Blood 2011, 118. Abstract 118 [ASH Annual Meeting Abstracts].
36. Garcia-Manero G., Gore S.D., Cogle C., Ward R., Shi T., Macbeth K.J., et al. Phase I, study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011, 29(18):2521-2527.
37. Qin T., Castoro R., El Ahdab S., Jelinek J., Wang X., Si J., et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE 2011, 6(8):e23372.
38. Yoo C.B., Jeong S., Egger G., Liang G., Phiasivongsa P., Tang C., et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007, 67(13):6400-6408.
39. Nilsson L., Edén P., Olsson E., Månsson R., Astrand-Grundström I., Strömbeck B., et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007, 110(8):3005-3014.
40. Sun S., Schiller J.H., Spinola M., Minna J.D. New molecularly targeted therapies for lung cancer. J Clin Invest 2007, 117(10):2740-2750.
41. Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011, 11(7):493-501.
42. Xu F., Yang R., Wu L., Wu L., He Q., Zhang Z., et al. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome. Cancer Lett 2012, 317(1):33-40.
43. Xu F., Li X., Wu L., Zhang Q., Yang R., Yang Y., et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011, 90(6):643-653.
44. Mihara K., Chowdhury M., Nakaju N., Hidani S., Ihara A., Hyodo H., et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006, 107(1):305-308.
45. Jamieson C., Cortes J.E., Oehler V., Baccarani M., Kantarjian H.M., Papayannidis C., et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. Blood 2011, 118. Abstract 424 [ASH Annual Meeting Abstracts].